Pinnacle Wealth Planning Services
IKT icon

Pinnacle Wealth Planning Services’s Inhibikase Therapeutics IKT Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.1K Hold
5,400
– – ﹤0.01% 2045
2026
Q2 		$11K Hold
5,400
– – ﹤0.01% 2030
2026
Q1 		$9.07K Hold
5,400
– – ﹤0.01% 2041
2025
Q4 		$11.1K Buy
+5,400
New +$8.59K ﹤0.01% 1970

Other funds holding IKT

Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
SJS Investment Consulting
SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Pinnacle Wealth Planning Services's IKT Position: Q3 2026 in Review

Pinnacle Wealth Planning Services held its Inhibikase Therapeutics (IKT) position steady in Q3 2026 at 5,400 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

Pinnacle Wealth Planning Services first reported a position in IKT in Q4 2025 and has held it in 4 quarters since. 10 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

  • Pinnacle Wealth Planning Services held 5,400 shares of Inhibikase Therapeutics worth $11.1K as of Q3 2026.
  • Pinnacle Wealth Planning Services left its Inhibikase Therapeutics share count unchanged in Q3 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q3 2026, its #2045 holding.
  • Pinnacle Wealth Planning Services first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 10 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q3 2026, filed 27 Oct 2026.